Menu
Recruiting NCT07313462

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

— Observational Multiple Sclerosis (MS)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Multiple Sclerosis (MS). Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Primary outcome measures

  • Time to First Clinical Inflammatory Relapse [Time frame: Up to 12 months]

Eligibility criteria

Inclusion criteria

  • Patients with RRMS onset after age 50
  • Patients who started their first disease-modifying therapy within 2 years of the first symptoms
  • Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
  • Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Exclusion criteria

\- Patients with early progressive MS

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

France · 1 center
  • Centre d'Investigation Clinique - CHU de Strasbourg - France — Strasbourg

Identifiers

NCT: NCT07313462 · 9535

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗